Klanova, M.* et al. Anti-apoptotic MCL1 protein represents critical survival molecule for most Burkitt lymphomas and BCL2-negative diffuse large B-cell lymphomas. Mol. Cancer Ther. 21, 89-99 (2021)
Helms, M.W.* et al. Utility of the RIG-I agonist triphosphate RNA for melanoma therapy. Mol. Cancer Ther. 18, 2343-2356 (2019)
Grüner, B.M.* et al. Modeling therapy response and spatial tissue distribution of erlotinib in pancreatic cancer. Mol. Cancer Ther. 15, 1145-1152 (2016)
Liikanen, I.* et al. Oncolytic adenovirus expressing monoclonal antibody trastuzumab for treatment of HER2-positive cancer. Mol. Cancer Ther. 15, 2259-2269 (2016)
Deppisch, N. et al. Efficacy and tolerability of a GD2-directed trifunctional bispecific antibody in a preclinical model: Subcutaneous administration is superior to intravenous delivery. Mol. Cancer Ther. 14, 1877-1883 (2015)
Magin, S.* ; Papaioannou, M.* ; Saha, J.* ; Staudt, C. & Iliakis, G.* Inhibition of homologous recombination and promotion of mutagenic repair of DNA double-strand breaks underpins arabinoside-nucleoside analogue radiosensitization. Mol. Cancer Ther. 14, 1424-1433 (2015)
Pietschmann, K.* et al. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors. Mol. Cancer Ther. 11, 2373-2383 (2012)
Lee, M.S. et al. Levels of p27 sensitize to dual PI3K/mTOR inhibition. Mol. Cancer Ther. 10, 1450-1459 (2011)
Abiatari, I.* et al. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol. Cancer Ther. 8, 1494-1504 (2009)